Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.
A novel first-in-class antibody can significantly extend median survival when added to standard chemotherapy for patients with advanced gastric cancer.
Heavily pretreated women with metastatic breast cancer had significant improvements in progression-free survival and overall response rate when treated with the combination of utidelone plus capecitabine compared with capecitabine alone.
A targeted-sequencing gene panel that includes EGFR, KRAS, PIK3CA, and other mutations from circulating tumor DNA detects stage I non–small-cell lung cancer and might outperform existing tumor markers.
An antibody-drug conjugate, rovalpituzumab tesirine, shows promising efficacy against recurrent small-cell lung cancer.
Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.
A study testing the all oral combination of ixazomib, cyclophosphamide, and dexamethasone showed that patients with newly diagnosed multiple myeloma responded well to the experimental treatment regimen.
The FDA has approved the cobas® EGFR Mutation Test v2, the first “liquid biopsy” blood test for detecting EGFR gene mutations in non-small cell lung cancer.
The investigational biosimilar MYL-1401O has comparable efficacy and safety to the FDA-approved trastuzumab in metastatic HER2-positive breast cancer.
Details of a first-in-human case report showed that a patient with melanoma was able to achieve a durable complete response with the combination of two types of immunotherapy.